Acta materia medica最新文献_第3页

Prognostic value and immune infiltration analyses of cuproptosis-related genes in hepatocellular carcinoma 肝细胞癌中铜绿相关基因的预后价值及免疫浸润分析

Acta materia medica Pub Date : 2023-01-01 DOI: 10.15212/amm-2023-0035

Junjie Li, Shuoyi Ma, Yantao Zheng, Mengchen Qin, Hui Jia, Chang Liu, Yunjia Li, Guanghui Deng, Min Cai, Bin Liu, Lei Gao

{"title":"Prognostic value and immune infiltration analyses of cuproptosis-related genes in hepatocellular carcinoma","authors":"Junjie Li, Shuoyi Ma, Yantao Zheng, Mengchen Qin, Hui Jia, Chang Liu, Yunjia Li, Guanghui Deng, Min Cai, Bin Liu, Lei Gao","doi":"10.15212/amm-2023-0035","DOIUrl":"https://doi.org/10.15212/amm-2023-0035","url":null,"abstract":"The role of cuproptosis, a newly discovered form of programmed cell death, remains poorly understood in hepatocellular carcinoma (HCC). This study was aimed at constructing a novel cuproptosis model for analyzing the clinical features, mutation characteristics and immune profile of HCC associated with cuproptosis-related genes (CRG), and to analyze the prognostic value of CRGs in HCC. We comprehensively evaluated HCC datasets containing clinicopathological information from The Cancer Genome Atlas and GEO, on the basis of 19 CRGs. The prognostic value of the cuproptosis-related risk score was established. Our results revealed two clusters associated with cuproptosis. Cluster B exhibited pronounced isolated innate immune cell infiltration and poor prognosis, and significant differences in prognosis and immune infiltration were observed between the groups with high and low cuproptosis risk. High copper mortality risk scores were associated with an elevated tumor mutational burden (TMB) and poor prognosis. Our findings suggest that evaluating copper-death subtypes provides insights into CRGs. Moreover, the copper mortality risk score model aids in characterizing prognosis and immune infiltration independently of the TMB.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134884305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efgartigimod, an FcRn antagonist, as a potential treatment for post COVID-19 syndrome Efgartigimod，一种FcRn拮抗剂，作为COVID-19后综合征的潜在治疗

Acta materia medica Pub Date : 2023-01-01 DOI: 10.15212/amm-2023-0004

S. Reznik, A. Tiwari, C. Ashby

{"title":"Efgartigimod, an FcRn antagonist, as a potential treatment for post COVID-19 syndrome","authors":"S. Reznik, A. Tiwari, C. Ashby","doi":"10.15212/amm-2023-0004","DOIUrl":"https://doi.org/10.15212/amm-2023-0004","url":null,"abstract":"A significant proportion of patients who survive coronavirus disease of 2019 (COVID-19) develop a constellation of life-altering symptoms that persist long after the initial infection has resolved. This post-COVID-19 syndrome may result from the development of autoreactive IgG antibodies that cause inflammation and tissue injury. In this commentary, we suggest that efgartigimod, a drug approved for the treatment of generalized myasthenia gravis, be tested for use in patients with post-COVID-19. Efgartigimod is a humanized IgG Fc fragment containing five point mutations that significantly increase affinity for the Fc region of the neonatal crystallizable fragment receptor (FcRn). FcRn is involved in the pathogenesis of autoimmune diseases via the IgG recycling pathway because FcRN binds to autoreactive IgG antibodies and prevents the antibodies from being catabolized. Efgartigimod is a modified immunoglobulin that competitively displaces endogenous IgG from FcRn, thus increasing the level of unbound IgG, which is then catabolized and leads to decreased circulating levels of autoreactive as well as normal IgG. We suggest that efgartigimod be evaluated in a random, double-blind placebo-control trial in adults with post-COVID-19 for at least 2 months. If re-purposing this myasthenia gravis-approved drug for post - COVID-19 is successful, additional bioengineered FcRn antagonists should be tested for efficacy in patients with post-COVID-19.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67303138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

ZnPc photosensitizer-loaded peony-shaped FeSe2 remotely controlled by near-infrared light for antimycobacterial therapy 近红外光遥控负载ZnPc光敏剂的牡丹形FeSe2抗真菌治疗

Acta materia medica Pub Date : 2023-01-01 DOI: 10.15212/amm-2023-0012

Peng Wu, Xiaoning Liu, Yuheng Duan, Liping Pan, Zhaogang Sun, Hong-qian Chu, Chuanzhi Zhu, Bei Liu

引用次数: 2

1,7-Bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one inhibits SARS-CoV-2 by targeting the nucleocapsid protein 1,7-二(4-羟基苯基)-1,4,6-庚三烯-3 -1通过靶向核衣壳蛋白抑制SARS-CoV-2

Acta materia medica Pub Date : 2023-01-01 DOI: 10.15212/amm-2023-0021

Yang Liu, Kuiru Sa, Wei-Na Xu, Yong-Quan Chen, Jing Liang, Peng Zou, Lixia Chen

{"title":"1,7-Bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one inhibits SARS-CoV-2 by targeting the nucleocapsid protein","authors":"Yang Liu, Kuiru Sa, Wei-Na Xu, Yong-Quan Chen, Jing Liang, Peng Zou, Lixia Chen","doi":"10.15212/amm-2023-0021","DOIUrl":"https://doi.org/10.15212/amm-2023-0021","url":null,"abstract":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally since 2020. The nucleocapsid (N) protein plays a crucial role in the life cycle of SARS-CoV-2. Here, we established a method to screen inhibitors of N protein by using microscale thermophoresis assays to obtain potential anti-SARS-CoV-2 agents. We identified 1,7-bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one (N-17, a diphenylheptane) as a compound with outstanding inhibitory activity. We further validated the binding of N-17 to the N-terminal domain of N protein (N-NTD) by using drug affinity responsive target stability assays. We evaluated the ability of N-17 to bind N protein and predicted the affinity of N-17 to the N-NTD with molecular docking and molecular dynamics simulation. N-17 exhibited excellent anti-viral activity against HCoV-OC43 and SARS-CoV-2, with EC50 values of 0.16 ± 0.01 μM and 0.17 ± 0.07 μM, respectively. Thus, we discovered a novel SARS-CoV-2 inhibitor targeting the N protein and validated its anti-viral activity in vitro. Our results may contribute to the development of promising therapeutic agents for COVID-19.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67303795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Sesquiterpenoids from the sunflower family as potential anti-inflammatory candidates: a review 向日葵科的倍半萜类化合物作为潜在的抗炎候选者:综述

Acta materia medica Pub Date : 2023-01-01 DOI: 10.15212/amm-2023-0026

Cheng Chen, Zheling Feng, Jovana Petrović, Marina Soković, Yang Ye, Ligen Lin

{"title":"Sesquiterpenoids from the sunflower family as potential anti-inflammatory candidates: a review","authors":"Cheng Chen, Zheling Feng, Jovana Petrović, Marina Soković, Yang Ye, Ligen Lin","doi":"10.15212/amm-2023-0026","DOIUrl":"https://doi.org/10.15212/amm-2023-0026","url":null,"abstract":"Inflammation is an essential part of the immune response to injury and infection. Emerging evidence indicates that long-term low-grade inflammation is positively correlated with many diseases, such as cancer, metabolic disorders, and cardiovascular diseases. Due to common anti-inflammatory drugs are suitable for treating acute inflammation and cause severe adverse effects, new safe and effective drug candidates are urgently needed for treating chronic inflammation. Plants of the Asteraceae family have been widely used in traditional medicines for relieving fever symptoms and killing pathogens. The anti-inflammatory properties of sesquiterpenoids from plants in the Asteraceae family have attracted increasing attention in recent decades because of their structural complexity and potent bioactivities. Herein, we provide a comprehensive and up-to-date summary of sesquiterpenoids from the Asteraceae family with anti-inflammatory properties, including their drug likeness and druggability, as analyzed with the SwissADME and ADMETlab online tools. In the future, some sesquiterpenoids might serve as therapeutic agents to treat inflammation-associated diseases.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135846122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Senescence-associated lncRNAs indicate distinct molecular subtypes associated with prognosis and androgen response in patients with patients with prostate cancer 衰老相关的lncrna表明不同的分子亚型与前列腺癌患者的预后和雄激素反应相关

Acta materia medica Pub Date : 2023-01-01 DOI: 10.15212/amm-2023-0025

Dechao Feng, Dengxiong Li, Jie Wang, Rui-cheng Wu, Chi Zhang

{"title":"Senescence-associated lncRNAs indicate distinct molecular subtypes associated with prognosis and androgen response in patients with patients with prostate cancer","authors":"Dechao Feng, Dengxiong Li, Jie Wang, Rui-cheng Wu, Chi Zhang","doi":"10.15212/amm-2023-0025","DOIUrl":"https://doi.org/10.15212/amm-2023-0025","url":null,"abstract":"Cellular senescence has been considered as a hallmark of aging. In this study, we aimed to establish two novel prognostic subtypes for prostate cancer patients using senescence-related lncRNAs. Nonnegative matrix factorization algorithm was used to identify molecular subtypes. We completed analyses using software R 3.6.3 and its suitable packages. Using SNHG1, MIAT and SNHG3, 430 patients in TCGA database were classified into two subtypes associated with biochemical recurrence (BCR)-free survival and subtype 2 was prone to BCR (HR: 19.62, p < 0.001). The similar results were observed in the GSE46602 and GSE116918. For hallmark gene set enrichment, we found that protein secretion and androgen response were highly enriched in subtype 1 and G2M checkpoint was highly enriched in subtype 2. For tumor heterogeneity and stemness, homologous recombination deficiency and tumor mutation burden were significantly higher in subtype 2 than subtype 1. The top ten genes between subtype 2 and subtype 1 were CUBN, DNAH9, PTCHD4, NOD1, ARFGEF1, HRAS, PYHIN1, ARHGEF2, MYOM1 and ITGB6 with statistical significance. In terms of immune checkpoints, only CD47 was significantly higher in subtype 1 than that in subtype 2. For the overall assessment, no significant difference was detected between two subtypes, while B cells score was significantly higher in subtype 1 than subtype 2. Overall, we found two distinct subtypes closely associated with BCR-free survival and androgen response for prostate cancer. These subtypes might facilitate future research in the field of prostate cancer.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67303509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Photoredox-catalyzed reaction as a powerful tool for rapid natural product Gem-dimethylation modification: discovery of potent anti-cancer agents with improved druggability 光氧化催化反应作为快速天然产物gem -二甲基化修饰的有力工具:发现具有改进药物性的强效抗癌药物

Acta materia medica Pub Date : 2023-01-01 DOI: 10.15212/amm-2023-0032

Chao Zhang, Yugang Song, Xiuyun Sun, Qianlong Liu, Zhen Li, Shenyi Yin, Jianzhong Jeff Xi, Xin Zhai, Yu Rao

{"title":"Photoredox-catalyzed reaction as a powerful tool for rapid natural product Gem-dimethylation modification: discovery of potent anti-cancer agents with improved druggability","authors":"Chao Zhang, Yugang Song, Xiuyun Sun, Qianlong Liu, Zhen Li, Shenyi Yin, Jianzhong Jeff Xi, Xin Zhai, Yu Rao","doi":"10.15212/amm-2023-0032","DOIUrl":"https://doi.org/10.15212/amm-2023-0032","url":null,"abstract":"Tylophorine has diverse biological activities; however, the stability, solubility, and central nervous system toxicity have severely limited use of tylophorine. The gem -dimethyl group is an organic chemistry functional group that consists of two methyl groups bonded to the same carbon atom. This feature has gained significant attention in medicinal chemistry due to its unique properties and potential applications in drug design. We applied a new photoredox methodology to tylophorine modification, resulting in a series of gem-dimethyl tylophorine analogues. Among the analogues, compound 4b demonstrated promising activity against a wide range of tumor cell lines and exhibited significantly improved drug-like properties, including enhanced solubility and stability. Compound 4b showed an exceptional inhibitory effect (7.8 nM) against a C481S mutation-induced ibrutinib-resistant non-Hodgkin’s lymphoma cell line, as well as primary tumor cell lines obtained from patients. Importantly, compound 4b exhibited significantly reduced anti-proliferative activity against the normal cell line tested, indicating the potential for an enhanced therapeutic window for compound 4b . Based on these early-stage data, we believe that our study provides a solid foundation for the development of new therapeutic agents for potential drug-resistant cancer treatment in the near future.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135261277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel emerging nano-assisted anti-cancer strategies based on the STING pathway 基于STING通路的新型纳米辅助抗癌策略

Acta materia medica Pub Date : 2023-01-01 DOI: 10.15212/amm-2023-0023

Xianghui Li, Haoran Wang, Yuanyuan Chen, Zhiyan Li, Song Liu, Wenxian Guan, Youkun Lin, Cunwei Cao, Wenjun Zheng, Jinhui Wu

引用次数: 0

Structure-based virtual screening for novel p38 MAPK inhibitors and a biological evaluation 新型p38 MAPK抑制剂的基于结构的虚拟筛选和生物学评价

Acta materia medica Pub Date : 2023-01-01 DOI: 10.15212/amm-2023-0028

Qinwen Zheng, Yumeng Zhu, Aoxue Wang, Panpan Yang, Xin Wang, Wen Shuai, Liang Ouyang, Guan Wang

引用次数: 0

Baseline differences in metabolic profiles of patients with lung squamous cell carcinoma responding or not responding to treatment with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) 纳米颗粒白蛋白结合紫杉醇(nab-paclitaxel)治疗对肺鳞癌患者代谢谱的基线差异

Acta materia medica Pub Date : 2023-01-01 DOI: 10.15212/amm-2023-0027

Peng Cao, Qilin Zhang, Sanlan Wu, Mitchell A. Sullivan, Yifei Huang, Weijing Gong, Yongning Lv, Xuejia Zhai, Yu Zhang

{"title":"Baseline differences in metabolic profiles of patients with lung squamous cell carcinoma responding or not responding to treatment with nanoparticle albumin-bound paclitaxel (nab-paclitaxel)","authors":"Peng Cao, Qilin Zhang, Sanlan Wu, Mitchell A. Sullivan, Yifei Huang, Weijing Gong, Yongning Lv, Xuejia Zhai, Yu Zhang","doi":"10.15212/amm-2023-0027","DOIUrl":"https://doi.org/10.15212/amm-2023-0027","url":null,"abstract":"Background: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a preparation widely used in chemotherapy for cancers. However, only some patients benefit from this treatment. Therefore, identifying which patients will respond to nab-paclitaxel therapy is crucial. Methods: A cohort of 32 patients with lung squamous cell carcinoma (LUSC) treated with nab-paclitaxel were enrolled in this study. Plasma samples were collected before chemotherapy and used to perform metabolomic and lipidomic analyses. Tumor response to two cycles of chemotherapy was evaluated. Metabolites differentially present among populations were screened and analyzed. Results: According to the RECIST criteria, one-third of patients had a significant response to nab-paclitaxel, whereas one-fifth showed no discernible benefit. According to the criteria of variable importance in projection >1 and fold change >2, we identified 61, 81 and 54 differential metabolites between the progressive disease (PD) vs partial response (PR), PD vs stable disease (SD), and SD vs PR groups, respectively. Moreover, we used three variation in logistic regression models and ROC diagnostic curves to identify optimal metabolites for stratifying patients with differing chemotherapeutic responses. The PD vs SD, SD vs PR, and PD vs PR groups were well separated on the basis of cis-9,10-epoxystearic acid/octapentaenoic acid (AUC 0.9330), salicyluric acid/DG (18:1/20:5/0:0) (AUC 1.0000) and D-glyceric acid/9,12-octadecadienoic acid (AUC 1.0000), respectively. Conclusion: The baseline metabolic profiles significantly differed between responder and non-responder patients with LUSC treated with nab-paclitaxel. These differential metabolites have the potential to predict the outcomes of patients with LUSC before chemotherapy.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135840026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0